CYTOTOXICITY ASSAYS IN ARTIFICIAL ORGANS

Abstract: Method and apparatus for fluorimetrically determining the efficasy of therapeutic agents in an artificial capillary or membrane-type cell culturing apparatus. The advantage of this determination is that it produces results which more closely approximate those in vivo. Biopsied cells are introduced into the culturing apparatus and then exposed to therapeutic agents and a fluorogenic substrate. Changes in fluorescence are monitored and provide an indication of the sensitivity of the cells to the therapeutic agent.

Description: CYTOTOXICITY ASSAYS IN ARTIFICIAL ORGANS Technical Field This invention relates to methods and devices for predicting the in vivo responsiveness of abnormal cells to cytotoxic agents based on in, vitro culture assessments. Background of the Invention It is known that cancerous or otherwise abnormal cells of identical histopathological type show a wide range of responsiveness to particular drug therapies among individual patients. Predictive techniques, similar to the culture and sensitivity assays used for the management of microbial infections, would be of great assistance in selecting effective chemotherapy for individual cases. Without individualized anti-cancer drug regimens, practitioners are forced to rely on past experience or reports on similar cell disorders or trial-and-error procedures. With the increasing number of anti-cancer agents available and the limited time often available for modifying doses or agents, the task of selecting the optimal regimen, without the aid of predictive assays, is very difficult. A number of predictive systems have been proposed. See, for example, Salmon e_fc, aJ_- * . » "Quantitation of Dif¬ ferential Sensitivity of Human Stem Cells to Anti- cancer Drugs," Vol. 293 New England Journal £f Medicine pp. 1321-1327 (1973). Typically, the prior art tech¬ niques involve the cloning of single cell suspensions from biopsy specimens in soft agar after brief exposure to particular anti-cancer drugs. See also, Buick e_£ al.. "Development of an Agar-Methyl Cellulose Clonoge- nic Assay for Cells in Transitional Cell Carcinoma of the Human Bladder," Vol. 39 Cancer Research pp. 5051- 5056 (1979) and Von Hoff £ aj^, "Direct Cloning of Human Malignant Melanoma in Soft Agar Culture," Vol. 50 Han p r pp. 695-701 (1932), for further details on agar culture techniques. Various difficulties limit the usefulness of agar culture studips for predicting thp ef ectiveness of cytoxic agents against abnormal cells. Only a small fraction of biopsipd cancer cells grow in soft agar. For pxa plp, when cell suspensions from myeloma speci¬ mens arp plated in agar. plating efficiencies of 1:1000 are not uncommon. Thus, for statistically significant rpsults comparing different drugs at different doses, large numbers of cells are required. It is also not certain that colonies formed in agar will be derived from the most .malignant tumor cells. Moreover, agar techniques typically limit drug exposure to a relative¬ ly brief period (i.e., one hour) prior to plating while the cell is suspens p d in a physiological solution. Neither the exposure technique nor the subsequent growth in agar accurately mimic in, vivo conditions. Additionally, the time required for evaluation is long (i.e., 14 to 30 days) compared to th p often urgent need to establish a protocol for therapy. Finally, measure¬ ments of drug sensitivity by counting cell colonies can be subjective, statistically inaccurate and time consu¬ ming. Another predictive system which has been proposed for chemotherapy studies involves the use of cell cul¬ tures grown in an artificial organ made of a matrix of synthetic capillaries. Quartles e£ al.. "Hemodialysis- Matrix Perfusion Culture System: A New Technique for Studying Chemotherapβutic Activity Tumor Cells," Vol. 16 In Vitro 246 (1930), report the effect of one anti- cancer agent on tumor cells grown in an artificial organ system (Amicon-Vitafiber (R)). Following expo¬ sure to the drug, the cultured cells were removed from the organ and assayed for total and viable cells, colony forming ability and growth in soft agar. Synthetic capillary systems have advantages over soft agar techniques in presenting a culture more simi¬ lar to the in vivo environment and permitting the introduction of drugs into the culture via the ca¬ pillaries in a fashion more like the perfusion of active agents in a patient. For a review of capillary cultures, generally, see Schratter, "Cell Culture with Synthetic Capillaries," Vol.XIV Methods in Cell Biology pp. 95-103 (1976), herein incorporated by reference. The capillary technique for studying che otherapeu- tio activity reported by uartles, supra, is still subject to many of the same problems that limit the usefulness of agar studies. Quartles and his co- workers had to remove the cells from the capillary system in order to count total and viable cells. In practice, removing cells without damage from a capil¬ lary matrix is an ardent task. Typically, the cells are removed from the capillary matrix by enzyme treat¬ ment but this treatment can be more effective on dead cells than on living cells and quantitative results are difficult to obtain. Moreover,, the culture is lost after enzyme treatment and can not be used again. Additionally, once the cells are removed, counting viable cells under a microscope again can be subjective and inaccurate and certainly is time consuming. A drug sensitivity test which relies on visual observations of live cells is very unlikely to find widespread clinical OMPI application.. There exists a need for simple, efficient methods and apparatus for predicting the n vivo responsiveness of cancerous and otherwise abnormal cells to therapeu¬ tic agents. The predictive culture system should be easily innoculated while cell growth and drug exposure should mimic closely the human environment. More im¬ portantly, the drug sensitivity should be quantifiable by a simple and accurate method in a relatively short time and preferably in a way that would permit a clini¬ cian to obtain a reading on the effectiveness of a particular agent without destruction of the culture so that the effects of a multi-step protocol (i.e., va¬ rying in agents or doses) can be measured sequentially. Summary of the Invention A simple, sensitive, cytotcrxicity assay capable of widespread clinical application is disclosed. The method claimed herein permits the clinician to assess cell viability in an artificial organ. The number of living cells in the organ is evaluated by measuring the retention of fluorescein or a similar label by the cell membranes. In a preferred embodiment the cultured cells are allowed to accumulate fluorescein through fluorochromasia. Specifically, fluorochromasia occurs when a fluoro- genic substrate, typically a nonpolar fluorogenic sub¬ strate such as an ester of fluorescein and an aliphatic acid, is introducted into a cell culture. The fluoro¬ genic substrate penetrates the cell membranes where it is enzymatieally hydrolyzed, liberating fluorescein and staining the cell brightly fluorescent under blue light. Since fluorescein, a negatively charged mole- cule, does not diffuse readily across the cytoplasmic membrane of : normal cells, the process causes intracel- lular accumulation of fluorescein. See, generally, an article by the inventor and another entitled "Membrane Properties of Living Mammalian Cells as Studied by Enzymatic Hydrolysis of Fluorogeniσ Esters", Vol. 55, No. 1, Proceedings of the National Academy of Sciences pp. 134-141 (1966). However, when a dead cell is treated with the fluorogenic substrate, no intracellu- lar accumulating of fluorescein is observed. Therefore, if the cells in the artificial organ have been killed by an agent prior to the introduction of a fluorescent substrate, hydrolysis of the substrate will not result in intracellular fluorescein accumulation. Thus, my method of measuring the responsiveness of cell cultures to cytotoxic agents resides in monitoring changes in the rate of fluorescein released by the cultured cells. In one aspect my invention consists of an appara¬ tus, i.e., an artificial organ, for culturing biopsied cells. Trie organ includes at least one perfusion ca¬ pillary or membrane surface and is preferably struc¬ tured so that it may be innoculated with undissoσiated fragments of biopsied tissues, thus retaining the basic cellular composition of the tumor (many tumors have been shown to exhibit cellular heterogeneity) . The perfusion of oxygen and nutrients as well as the three dimensional structure of the artificial organ make it likely that even tumor cells unable to grow in agar will proliferate. Moreover, given the sensitivity of fluorescence detection devices, the organ may be de¬ signed to accept small numbers of cells, thus permit¬ ting more simultaneous studies from biopsy specimens of limited size, such as colon cancer biopsies or infant OMPI cell biopsies. In another aspect my invention encompasses a system for performing cytotoxicity studies including a culture medium or organ wherein the biopsied cells may be grown, means for providing oxygenated nutrients to the organ, means for introducing the fluorogenic substrate into the organ, means for introducing anti-cancer a- gents into the organ and means for measuring the re¬ leased fluorescence. Preferably, fluorescence is mea¬ sured by a fluorimeter and the data collected auto¬ matically and evaluated by a computer shortly after innoculation of the organ with the anti-cancer agent. Although my invention can be practiced with a single- purpose machine, clinics with fluorimeters and general- purpose computers could also employ my system by ob¬ taining Kits containing the culture organ and fluoroge¬ nic substrates. Moreover, although my preferred embodiment is one in which the culture organ has a limited number of perfusion capillaries or surfaces and is designed for innoculation with a small number of biopsied cells, other cell culturing devices can be substituted. See for examples of cell culturing devices: U.S. Patent 3,321,087 issued to Knazek ££ al. on June 23, 1974 for Semi-Permeable Membranes; U.S. Patent 3 * 353,712 issued to House on December 10, 1974 for Cell Culture Systems; U.S. Patent 3,943,732 issued to Haddad & al♦ on April 6, 1976 for Cell Culture Assembly; U.S. Patent 4,184,922 issued to Knazeic e_£ al. on January 22, 1930 for Woven Capillary Bundles; U.S. Patent 4,201,845 issued to Feder e& al. on May ό, 1930 for Cell Culture Reactor; U.S. Patent 4,220,725 issued to Knazek e£ al. on September 12, 1930 for Capillary Device; U.S. Pa- OMPI tent 4,241,-187 issued to White on December 23, 1930 for Apparatus for Tissue Culture; and U.S. Patent 4,308,351 issued to Leighton on December 29, 1931 for Growing Tissue System, the teachings of these referen¬ ces are herein incorporated by reference. The method of my invention may be practiced in a variety of ways. With chemotherapeutic agents that exhibit rapid action, the organ can be innoculated and the culture which grows thereon can then be perfused with a fluorogenic substrate until the cells become highly fluorochromatic (about 15 minutes). The perfu¬ sion then reverts to growth medium and the efflux of fluorescein from the cells is monitored until a steady state condition is reached. Next, the rapid action agent is introduced into the organ (either directly or by perfusion) and the σytotoxic effects immediately measured by changes in the efflux. Alternatively, with agents exhibiting delayed (i.e., radiomimetic ) effects, more detailed records of the kinetics and fluorescence of the efflux would be obtained for the organ following each of a series of perfusions with fluorogenic substrate. The slower agent would then be introduced into the organ for a given length of time (which may vary from minutes to days). Next the perfusion of fluorogenic substrate is repeated and variations from the base-line readings of fluorescence kinetics measured to determine the number of living cells remaining in the organ and, hence, sensi¬ tivity to the drug. It should be clear that these two techniques can be used in conjunction or modified in a number of ways without departing from my fundamental teachings. The various therapeutic or chemical agents which may be tested according to my invention for effective¬ ness on individual cell cultures include: adriamycins, mitomycins, actinomycins, neomycins, vincristine, vin- blastine, chlorambuσil, cis-platinu , 6-mercapto pu- rine, methotrexate, cyclophosphamide, melphalen, carmu- stine, methyl ester DOPA, BCNU, DTIC, 5-fluoruracil, m- AMSA, mitoxantrone, methyl GAG, acivicin, thymidine, hormones, antibodies, prostaglandins and lymphoines as well as X-rays or other agents as they become available. The efflux of fluorescent material from the organ can be measured by samples taken from the return stream of the perfusion network (since the fluorescent ma¬ terials will pass through the capillaries or membranes) or by sampling the cell compartment directly. In prac¬ tice it has been found that readings of fluorescence may be up to four times stronger in samples taken directly from the cell compartment. My method permits a clinician to test the effects of prolonged, different combinations and programmed schedules of drugs. Addi¬ tionally, with my system if a drug gives a negative cytotoxicity test, the artificial organ may serve for subsequent drug testing. Moreover, one may chose to measure fast or slow release of fluorescein by using fluorogenic substrates synthesized with different fluo¬ rescein derivates. For example, using fluorescein diacetate the half-life of intracellular fluorescence is about 45 minutes (at 37° C.) while with 6- carboxyfluorescein diacetate the half-life is extended to more than 8 hours. Temperature also has a modula¬ ting effect on fluorochromasis and, therefore, may be used to control the fluorescein efflux. For a tabula- OMPI tion of various fluorescein derivatives and their com¬ parative kinetics, see the discussion in Rotman and Papermaster, surra. Vol. 55 Proc. Nat. Acad. Sci. pp. 134-141 (1966). In a similar manner, other fluorogenic compounds can be employed. The invention will next be described in connection with certain preferred embodiments and experimental results; however, it should be clear that various chan¬ ges and modifications can be made without departing from the spirit and scope of the claims. For example, while my preferred embodiment involves the innoculation of the culture organ with undissoσiated fragments of biospied tissue, single cell suspensions also may be used to innoculate the culturing organ. Additionally, a wide variety of commercially avai¬ lable growth media from companys such as Gibco Corpora¬ tion and others may be employed as nutrients. These media are sold under names such as Dulbecco's Modified Eagle Medium (DMSM), Roswell Park Medium (RPMI) and Minimal Eagle Medium (MEM) and typically consist of amino acids, salts, vitamins, blood serum and other nutrients. Alternatively, in clinical applications, it may be preferred to use serum from the biopsied patient for all or part of the growth medium in order to fur¬ ther mimic in, vivo exposure to the agents undergoing testing. Moreover, while a primary objective of this in¬ vention is to present methods and apparatus for predic¬ ting the responsiveness of cancer cells to σhemothera- peutic agents, other uses may also prove valuable. For examples, drugs against other cell abnormalities may also be tes ' ted and my method may also be used in asses¬ sing the effects of drugs on non-cancerous cells as a measure of the side-effects that a particular course of chemotherapy would cause in the patient. Additionally, in the event that artificial organs become feasible as implantable substitutes for human organs rather than just cell culturing vessels, my invention provides an ideal method for testing such organs prior to implanta¬ tion. Brief Description of the Drawings Fig. 1 is a schematic drawing of a cell culturing organ which may be employed in my invention. Figs. 2a and 2b are schematic side and top drawings of an alternative cell culturing organ which may be employed in my invention. Fig. 3 is a schematic drawing of the culture assa¬ ying system of my invention;. Fig. 4 is a graph of fluorescent activity for a cell culture before and after treatment with cytotoxic a- gents according to the invention. Detailed Description of the Preferred Embodiments With reference to Fig. 1, a culturing apparatus or organ 10 is shown comprising a cell compartment 12, capillaries 18 and shell 24. The capillaries 18 are sealed to the shell 24 by sealing means 26. In opera¬ tion cells may be innoculated into the organ 10 via port 14 and washed out via port 16 (or a single port could also be used) while a growth medium and agents pass from inlet 20 to outlet 22 via the capillaries 18. In Fig 2 an alternative organ 30 is shown with a cell compartment 12 surrounded by two flat membrane sheets 32 and a shell 24. The membrane sheets 32 are sealed to the shell 24 by sealing rings 34. Supports or cappiliaries (not shewn) may be inserted in compartment 12 to keep the membranes apart and supply extra nutrients. In opera¬ tion, cells, as well as fluorogenic substrate and wa¬ shing solutions, may be introduced into the cell com¬ partment 12 via inlet 42 through valve 44. Nutrients are circulated through the ports 62 independently or in series as shown with hosing 64 connecting the upper nutrient chamber 66 and the lower chamber 68'. Inside the organ, nutrients perfuse across the membranes 32 to feed the cultured cells. Fluorogenic measurements may be taken by opening valve 46 while the nutrients are cycled through the organ. The perfusion flow provides a steady efflux stream flowing out of port 48. The culturing apparatus of my invention can take a variety of other forms. Capillaries may be formed of any of a variety of semi-permeable materials, such as cellulose acetate, polycarbonates, polysulfone, or acrylic σopolymers, and may be coated with materials such as collagen to promote cell attachment, if de¬ sired. Capillaries are available from a variety of manufacturers including A icon Corporation, Dow Chemi¬ cal Corporation, Flow Laboratories or Bio-Rad Laborato¬ ries and have selectively permeable thin walls permit¬ ting unhindered passage of electrolytes, salts, dissol¬ ved gases, and therapeutic agents while restricting macromolecules of 10,000 to 100,000 daltons. They typically have walls 25-75 microns thick and have inte¬ rnal diameters of about 200 microns. Additionally, companies such as Ethicon, Inc., Millipore Corporation, Nucleopore Corporation and others manufacture membrane surfaces having similar selectively permeable walls. Preferrably, the capillary or membrane material should exhibit low absorption of the fluorogenic substrate since absorption and spontaneous hydrolysis will lead to higher background fluorescence. In addition, the volume of the organ is preferrably small, i.e., a capacity for 2000 to 100,000 cultured cells should suffice. In Fig. 3, one embodiment of the fluoroohromatic system 40 of my invention is shown. Organ 10, compri¬ sing perfusion means 18 and cell compartment 12 may be innoculated with cells via ports 14. The cells are provided with nutrients and the agents to be tested via the influx stream 3 while the efflux stream 36 is monitored by fluorimeter 50. Typically, the fluorime- ter 50 comprises a light source 52, focusing lens 54 and 56, a photomultiplier tube 53 and associated compu¬ tational and display means 60 (which may be built-in or separate) . After passing through the fluorimeter 50, the efflux stream 36 then returns to a reservoir 70 where the nutrients are replenished,and then is pumped via pump 72 through a gas diffusion means 74 (silicone tubing may be used to provide oxygen and carbon dioxide to the growth medium) and returned to the organ 10 as influx stream 34. Alternatively, fluorimeter samples may be taken from port 14 or 16. The or^an may be- enclosed in an incubator (not shown) to control organ temperature. Agents to be tested may be introduced directly into the cell compartment via ports 14, or indirectly via the influx stream 34 or by adding the agent to the growth medium reservoir 70 (which is preferred for obtaining dilutions comparable with in vivo condi¬ tions). If necessary the cells can be removed from the organ by enzyme detachment (i.e., interior circulation of trypsin) "and flushing. In one set of experiments the system of Fig. 3 was tested using a commercially available capillary device (Amicon Vitafiber(R) 3x50 Model) as the cultu¬ ring organ. Although the Amicon device had more capil¬ laries than necessary, the acrylic copolymer capilla¬ ries performed well in passing minimal Eagle Medium (MEM) and fluorogenic substrate to cultured myeloma cells. Fluorescein monoacetate (FMA) was used as the substrate rather than fluorescein diacetate (FDA) be¬ cause FDA produced background fluorescence due to non¬ specific absorption and hydrolysis at the highly hydro- phobic capillaries. This problem was alleviated by the use of FMA which has a free oarboxyl group and is considerably more polar. (Previous studies have shown that FMA is as- good a substrate as FDA but its use has been limited due to its intrinsic fluorescence; in my method, however, the FMA fluorescence is not bothersome but rather may be used to monitor FMA concentration). In other applications, it may be preferred to use fluorescein derivatives or fluorogenic substrates in conjunction with less capillaries or less absorbent capillary materials. The organ culture formed by the Amicon 3x50 device permitted perfusion of molecules up to 50,000 daltons and the fluid in the cell compartment was driven by the pressure generated inside the fibers. This condition was found to be more favorable for sampling in the cell compartment without disturbing the cells. In other applications, less or more permeable nutrient-circula¬ ting means may be preferred. Using FMA as a fluoroge¬ nic substrate, substantial fluoroohromatic differences OMP V& WIP were observed between devices containing live cells and controls. A protocol was established whereby the fluorogenic substrate was introduced at room temperature and then most of the initial fluorescence washed away. After washing the unit was shifted to 37° C and the kinetics of fluorescein efflux monitored. The rationale for this step was that cells excrete fluorescein 10 times faster at 37° C rather than 27° C while the rate of residual fluorescence shed by the capillary fibers was less affected by temperature. The test agent was then in¬ troduced and the steps of introducing the fluorogenic substrate, washing and monitoring repeated with changes in the fluorochromatic kinetics noted. In Fig. 4 , the results of treatment with formal¬ dehyde and methotrexate are shown. The darkened dots indicate measurements of fluorescence taken with the system described above before any agent was introduced (base-line data) while the white centered dots indicate fluorochromatic kinetics after treatment with formalde¬ hyde. As can be seen, the living cell culture exhi¬ bited a large spike of excreted fluorescence as soon as the temperature was increased to 37° C. Once exposed to the agent, the culture showed significantly less fluo¬ rescence after the temperature shift, indicating that the agent was effective in killing the cells and the culture was no longer able to exhibit fluorochromasia. The results of this experiment were confirmed by visual observations of the cells using conventional viability tests after removing them from the organ. The darkened boxes indicate fluorochromatic kinetics after treatment of a similar organ unit with a methotrexate agent (0.9 micrograms per milliliter) for 36 hours. In clinical use my system entails the distribu¬ tion of a : biopsy sample into one or more culture or¬ gans. Once the cultures grow to steady state condi¬ tions, a base-line or unit profile is obtained for each unit. (The base-line may vary due to the number and composition of cells). After profiling, the drugs to be tested are introduced into the units and changes in the profile reflect the sensitivity of the cell cul¬ tures to each drug. If no effects (or minimal ef¬ fects) are observed, then different drugs, higher doses or synergistic combinations may be tested using the same units again. What I claim is:

Claims: Claim 1. A method of assaying the sensitivity of biopsied cells to therapeutic agents. The method comprising. (a) culturing the cells in an artificial organ; (b) contacting the cells with a fluorogenic substrate, whereby living cells accumulate a characte¬ ristic amount of fluorescence; (o) introducing the agent into the organ; and (d) measuring changes in the fluorescence eluted from the organ as a indicator of the sensitivity of the cells to the agent. Claim 2. The method of Claim 1 wherein the step of measuring changes in fluorescence further comprises measuring the fluorescence eluted after contacting the cells with the substrate but prior to introducing the agent and then comparing this measurement with a second measurement of eluted fluorescence after a second contact with the substrate subsequent to intro¬ ducing the agent. Claim 3. The method of Claim 1 wherein the step of measuring changes in fluorescence further comprises measuring changes in the quantity of fluorescent acti¬ vity. Claim 4. The method of Claim 1 wherein the step of measuring changes in fluorescence further com¬ prises measuring changes in the kinetics of fluorescent activity. Claim 5. The method of Claim 1 wherein the method further comprises varying the temperature of the organ prior to measuring changes in fluorescence. Claim 6. The method of Claim 1 wherein the step CMPI of contacting the cells with a fluorogenic substrate further comprises contacting the cells with a fluore- scein-containing compound from which fluorescein is liberated upon hydrolysis. Claim 7. The method of Claim 1 wherein the step of contacting the cells with a fluorogenic substrate further comprises contacting the cells with at least one substrate chosen from the group of fluorescein diacetate, fluorescein onoacetate and derivatives thereof, from which substrate fluorescein is liberated after uptake and hydrolysis in the cell. Claim 3. The method of Claim 1 wherein the step of culturing the cells further comprises culturing the cells in an artificial organ having a cell compartment into which oxygenated nutrients are provided by perfu¬ sion. Claim 9. The method of ' Claim 8 wherein the nutrients are perfused into the cell compartment by at least one semi-permeable capillary vessel. Claim 10, ■ The method of Claim 9 wherein the nutrients are perfused into the cell compartment by at least one semi-permeable membrane surface. Claim 11. The method of Claim 1 wherein the step of culturing the cells further comprises culturing the cells in an artificial organ having a cell compartment into which oxygenated nutrients are provided by perfu¬ sion of a growth medium circulating through the organ and the step of measuring changes in the fluorescence eluted from the organ further comprises measuring fluoroescence in the growth medium downstream of the organ. Claim 12. An apparatus for testing the sensiti¬ vity of cells taken from a patient to a therapeutic agent, the apparatus comprising: ' (a) an artificial culturing organ wherein the cells may be grown; (b) means for providing oxygenated nu¬ trients to the organ; (c) means for introducing a fluorescence- inducing compound into the organ, whereby living cells will accumulate a characteristic amount of fluo¬ rescence; (d) means for introducing the agent into the organ whereby a portion of the cultured cells will be killed; and (e) means for measuring eluted fluorescence as an indicator of the cell culture's sensitivity to the agent. Claim 13. The apparatus of Claim 12 wherein the apparatus further comprises means for varying the tem¬ perature of the organ. Claim 14. The apparatus of Claim 12 wherein the means for providing oxygenated nutrients further com¬ prises at least one semi-permeable capillary vessel. Claim 15. The apparatus of Claim 12 wherein the means for providing oxygenated nutrients further com¬ prises at least one semi-permeable membrane surface. Claim 16. The apparatus of Claim 12 wherein the means for providing oxygenated nutrients comprises a semi-permeable circulation system within the organ in contact with the cells and a reservoir of growth me¬ dium, a pump and a gas diffuser outside the organ. Claim 17. The apparatus of Claim 12 wherein the means for providing oxygenated nutrients and the means for introducing a fluorescence-inducing compound both comprise a semi-permeable circulation system with the organ. Claim.18. The apparatus of Claim 12 wherein the means for measuring eluted fluorescence is a fluorime¬ ter. Claim 19. A cell culturing organ for use in fluorochromatic cytotoxicity assays, comprising: (a) a shell capable of containing cultured cells; (b) at least one port for innoculating a small number of biopsied cells into the shell; (c) a semi-permeable circulation system within the shell for providing oxygenated nutrients and fluorochromatic substrate to the cells; and (d) input and output ports for introducing and removing the circulating fluids from the shell. Claim 20. The organ of Claim 19 wherein the organ further comprises at least one port.for sampling the fluids within the shell. Claim 21. The organ of Claim 19 wherein the organ further comprises at least one port for washing cells from the shell. Claim 22. A kit for performing fluorochromatic cytotoxicity assays on cultured cells, the kit compri¬ sing: (a) an organ comprising a shell, a port for innocula_ting cells into the shell, a semi-permeable circulation system and input and output ports for in¬ troducing and removing circulating fluids from the shell; and (b) at least one fluorogenic substrate for use in the circulation system of the organ. Claim 23. The kit of Claim 22 wherein the fluo¬ rogenic substrate is at least one substrate chosen from the group of fluorescein diacetate, fluorescein monoa- cetate and derivatives thereof. OMP

Inventors: ROTMAN BORIS M, ROTMAN, BORIS, M.
Applicants: UNIV BROWN RES FOUND, BROWN UNIVERSITY RESEARCH FOUNDATION
Application year: 1984
Main classification: A61M1
IPC codes: C12M1, C12N5, C12Q1, G01N21, G01N33